Treatment drop-in in a contemporary cohort used to derive cardiovascular risk prediction equations
Abstract
Background No routinely recommended cardiovascular disease (CVD) risk prediction equations have adjusted for CVD preventive medications initiated during follow-up (treatment drop-in) in their derivation cohorts. This will lead to underestimation of risk when equations are applied in clinical practice if treatment drop-in is common. We aimed to quantify the treatment drop-in in a large contemporary national cohort to determine whether equations are likely to require adjustment. Methods Eight de-identified individual-level national health administrative datasets in Aotearoa New Zealand were linked to establish a cohort of almost all New Zealanders without CVD and aged 30–74 years in 2006. Individuals dispensing blood-pressure-lowering and/or lipid-lowering medications between 1 July 2006 and 31 December 2006 (baseline dispensing), and in each 6-month period during 12 years’ follow-up to 31 December 2018 (follow-up dispensing), were identified. Person-years of treatment drop-in were determined. Results A total of 1 399 348 (80%) out of the 1 746 695 individuals in the cohort were not dispensed CVD medications at baseline. Blood-pressure-lowering and/or lipid-lowering treatment drop-in accounted for 14% of follow-up time in the group untreated at baseline and increased significantly with increasing predicted baseline 5-year CVD risk (12%, 31%, 34% and 37% in Conclusions CVD preventive treatment drop-in accounted for approximately one-third of follow-up time among participants typically eligible for preventive treatment (≥5% 5-year predicted risk). Equations derived from cohorts with long-term follow-up that do not adjust for treatment drop-in effect will underestimate CVD risk in higher risk individuals and lead to undertreatment. Future CVD risk prediction studies need to address this potential flaw.Keywords
Funding Information
- Chinese Scholarship Council (202106010103)
- Heart Foundation of New Zealand Heart Health Research Trust Senior Fellowship (1886)
- Health Research Council of New Zealand (21/712)
This publication has 25 references indexed in Scilit:
- Comparison of American and European Guidelines for Primary Prevention of Cardiovascular DiseaseJACC, 2022
- Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participantsThe Lancet, 2021
- Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysisThe Lancet, 2021
- Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysisThe Lancet, 2021
- Prediction of Cardiovascular Disease Risk Accounting for Future Initiation of Statin TreatmentAmerican Journal of Epidemiology, 2021
- Association of Statin Use With All-Cause and Cardiovascular Mortality in US Veterans 75 Years and OlderJAMA, 2020
- Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trialsThe Lancet, 2019
- Can administrative health utilisation data provide an accurate diabetes prevalence estimate for a geographical region?Diabetes Research and Clinical Practice, 2018
- Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular DiseaseNew England Journal of Medicine, 2016
- Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trialsThe Lancet, 2015